About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Retatrutide
LY3437943
- Company
- Eli Lilly
- Mechanism
- triple GLP-1/GIP/glucagon
- Route
- Injectable
- Recruiting trials
- 2 recruiting
Next milestone: Regulatory filing (2026-Q4, estimated)
2 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Find a Clinical Trial Near Me
See recruiting studies for Retatrutide and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT07165028
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Not yet reported Eli Lilly and Company 4500 participants Est. completion 2032-08 563 sites Stand-aloneMASLDView official trial listing → -
Recruiting NCT NCT07467447
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Not yet reported Hudson Biotech 300 participants Est. completion 2028-02-17 1 site Stand-aloneOther conditions: ObesityView official trial listing → -
Completed NCT NCT03841630
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
Not yet reported Eli Lilly and Company 45 participants Est. completion 2019-07-25 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT04143802
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
Not yet reported Eli Lilly and Company 72 participants Est. completion 2020-12-28 4 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04823208
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
Not yet reported Eli Lilly and Company 64 participants Est. completion 2022-06-23 4 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04867785
A Study of LY3437943 in Participants With Type 2 Diabetes
Not yet reported Eli Lilly and Company 281 participants Est. completion 2022-10-27 43 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04881760
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Not yet reported Eli Lilly and Company 338 participants Est. completion 2022-11-22 28 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Completed NCT NCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
Not yet reported Eli Lilly and Company 32 participants Est. completion 2023-02-24 2 sites Stand-aloneOther conditions: ObesityView official trial listing → -
Completed NCT NCT05548231
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
Not yet reported Eli Lilly and Company 32 participants Est. completion 2023-07-27 2 sites Stand-aloneOther conditions: Overweight, ObesityView official trial listing → -
Completed NCT NCT05611957
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
Not yet reported Eli Lilly and Company 29 participants Est. completion 2023-09-05 4 sites Stand-aloneOther conditions: Healthy, Renal InsufficiencyView official trial listing → -
Completed NCT NCT05757531
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
Not yet reported Eli Lilly and Company 7 participants Est. completion 2023-06-23 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05882045
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Not yet reported Eli Lilly and Company 1946 participants Est. completion 2026-05-14 169 sites Stand-aloneCardiovascular disease Other conditions: ObesityView official trial listing → -
Completed NCT NCT05916560
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Not yet reported Eli Lilly and Company 43 participants Est. completion 2025-03-02 5 sites Stand-aloneOther conditions: Healthy, Hepatic InsufficiencyView official trial listing → -
Completed NCT NCT05929066
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Not yet reported Eli Lilly and Company 2335 participants Est. completion 2026-04-30 134 sites Stand-aloneOsteoarthritisObstructive sleep apnea Other conditions: Obesity, OverweightView official trial listing → -
Completed NCT NCT05929079
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Not yet reported Eli Lilly and Company 1152 participants Est. completion 2026-06-16 98 sites Stand-aloneType 2 diabetesObstructive sleep apnea Other conditions: Obesity, OverweightView official trial listing → -
Completed NCT NCT05931367
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Not yet reported Eli Lilly and Company 445 participants Est. completion 2025-11-14 49 sites Stand-aloneOther conditions: Obesity, Overweight, Osteo Arthritis KneeView official trial listing → -
Completed NCT NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Not yet reported Eli Lilly and Company 146 participants Est. completion 2025-10-21 42 sites Stand-aloneChronic kidney diseaseType 2 diabetes Other conditions: Overweight or ObesityView official trial listing → -
Completed NCT NCT05959096
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
Not yet reported Eli Lilly and Company 85 participants Est. completion 2024-07-25 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT06003465
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
Not yet reported Eli Lilly and Company 57 participants Est. completion 2024-02-08 3 sites Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Not yet reported Eli Lilly and Company 46 participants Est. completion 2024-07-11 2 sites Stand-aloneOther conditions: OverweightView official trial listing → -
Active, not recruiting NCT NCT06260722
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Not yet reported Eli Lilly and Company 1250 participants Est. completion 2027-01 77 sites Stand-aloneType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT06297603
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Not yet reported Eli Lilly and Company 320 participants Est. completion 2026-11 76 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT06313528
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
Not yet reported Eli Lilly and Company 85 participants Est. completion 2025-08-26 3 sites Stand-aloneOther conditions: ObesityView official trial listing → -
Completed NCT NCT06354660
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Not yet reported Eli Lilly and Company 537 participants Est. completion 2026-02-20 48 sites Stand-aloneOther conditions: Diabetes Type 2View official trial listing → -
Active, not recruiting NCT NCT06383390
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Not yet reported Eli Lilly and Company 10000 participants Est. completion 2029-02 743 sites Stand-aloneCardiovascular diseaseChronic kidney diseaseView official trial listing → -
Active, not recruiting NCT NCT06662383
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Not yet reported Eli Lilly and Company 800 participants Est. completion 2026-12 65 sites Stand-aloneOther conditions: ObesityView official trial listing → -
Completed NCT NCT06808802
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
Not yet reported Eli Lilly and Company 30 participants Est. completion 2025-04-15 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Active, not recruiting NCT NCT06859268
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Not yet reported Eli Lilly and Company 643 participants Est. completion 2028-04 53 sites Stand-aloneOther conditions: ObesityView official trial listing → -
Completed NCT NCT06982846
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Not yet reported Eli Lilly and Company 80 participants Est. completion 2026-05-04 1 site Stand-aloneType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT06982859
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Not yet reported Eli Lilly and Company 95 participants Est. completion 2026-12 1 site Stand-aloneOther conditions: Diabetes Mellitus, Insulin SensitivityView official trial listing → -
Active, not recruiting NCT NCT07035093
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Not yet reported Eli Lilly and Company 586 participants Est. completion 2027-09 40 sites Stand-aloneOther conditions: Obesity, Overweight, Chronic Low Back Pain (CLBP)View official trial listing → -
Active, not recruiting NCT NCT07232719
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Not yet reported Eli Lilly and Company 250 participants Est. completion 2027-07 31 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Active, not recruiting NCT NCT07357415
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Not yet reported Eli Lilly and Company 600 participants Est. completion 2028-11 35 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Available NCT NCT07629401
Pre-approval Expanded Access of Retatrutide (LY3437943)
Eli Lilly and CompanyOther conditions: Obesity, Obesity-related ComplicationsView official trial listing →
Efficacy history
Absolute change weight loss · 48 weeks
Adults with obesity or overweight, without type 2 diabetes
Trial: Phase 2 obesity trial (Phase 2)
Source →Results from different trials are not directly comparable — populations, timepoints, and measurement methods differ between studies.
Safety
Gastrointestinal adverse events (nausea, diarrhea, vomiting) were the most common, generally mild-to-moderate and more frequent at higher doses during dose escalation.
Source →Sources
Also known as: Retatrutide, LY3437943, Retatrutide (LY3437943)
Related On The Pen coverage
Latest stories
The Weekly Dose & livestreams
- $40 Zepbound?! China’s “Chokehold,” Retatrutide Anhedonia & More The Weekly Dose
- Retatrutide Biologic Battle: The Story Gets Bigger The Weekly Dose
- Eli Lilly’s Retatrutide Strategy Explained! Livestream
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.